Company: SMNR
Filing Date: 2025-08-08
Form Type: S-4/A
Source: 0001193125-25-177097
Chunk: 2

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-08
Form: S-4/A
Chunk 2
---
ant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

TABLE OF CO-REGISTRANTS

| Exact Name ofCo-Registrantas Specified in its Charter(1)(2) |     | State or OtherJurisdiction ofIncorporation orOrganization |          |     | PrimaryStandardIndustrialClassificationCode Number |      |     | I.R.S. EmployerIdentification Number |            |
| Semnur Pharmaceuticals, Inc.                                |     |                                                           | Delaware |     |                                                    | 2836 |     |                                      | 46-2968523 |

(1) The Co-Registranthas the following principal executive office: Semnur Pharmaceuticals, Inc. 960 San Antonio Road Palo Alto, CA 94303 (2) The agent for service for the Co-Registrantis: Jaisim Shah Chief Executive Officer and President Semnur Pharmaceuticals, Inc. 960 San Antonio Road Palo Alto, CA 94303 (650) 516-4310

The information in this preliminary proxy statement/prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary proxy statement/prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

<div align='center'>**PRELIMINARY — SUBJECT TO COMPLETION, DATED AUGUST 8, 2025

PROXY STATEMENT FOR

EXTRAORDINARY GENERAL MEETING

OF DENALI CAPITAL ACQUISITION CORP.

(A CAYMAN ISLANDS EXEMPTED COMPANY)

PROSPECTUS FOR

292,476,239 SHARES OF COMMON STOCK, 524,622 UNITS

6,000,000 SHARES OF SERIES A PREFERRED STOCK, AND 8,760,000 WARRANTS

OF

DENALI CAPITAL ACQUISITION CORP.

(AFTER ITS DOMESTICATION AS A CORPORATION INCORPORATED IN THE STATE OF DELAWARE), WHICH WILL BE RENAMED “